ACP
AMLX icon

Acuta Capital Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Acuta Capital Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.1M Sell
151,067
-182,191
-55% -$2.56M 1.48% 17
2025
Q4 		$4.03M Hold
333,258
– – 2.73% 12
2025
Q3 		$4.53M Buy
+333,258
New +$3.14M 4.68% 8

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Acuta Capital Partners's AMLX Position: Q1 2026 in Review

Acuta Capital Partners reduced its Amylyx Pharmaceuticals (AMLX) stake by 55% in Q1 2026, selling an estimated $2.56M and leaving 151,067 shares worth $2.1M. The position accounts for 1.48% of the portfolio, ranked #17.

Acuta Capital Partners first reported a position in AMLX in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.53M in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Acuta Capital Partners held 151,067 shares of Amylyx Pharmaceuticals worth $2.1M as of Q1 2026.
  • Acuta Capital Partners sold 182,191 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $2.56M.
  • Amylyx Pharmaceuticals made up 1.48% of Acuta Capital Partners's portfolio in Q1 2026, its #17 holding.
  • Acuta Capital Partners first reported a position in Amylyx Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Acuta Capital Partners's Amylyx Pharmaceuticals position peaked at $4.53M in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.